title: eEF2K--a new target in breast cancers with combined inactivation of p53 and PTEN.
abstract: Extensive efforts have now characterized the somatic molecular alterations in human breast cancer (Cancer Genome Atlas Network, 2012; Stephens et al, 2012) and have led to a re-definition of the disease as a constellation of 10 distinct driver-based subtypes (IntClust subtypes) (Curtis et al, 2012). The pursuit of druggable targets for each of these subtypes is now pressing. This is elegantly illustrated by the work of Liu et al (2014).
authors.affiliation: Department of Genetics, Institute for Cancer Research and Department of Pathology, Oslo University Hospital, Oslo, Norway K. G. Jebsen Center for Breast Cancer Research, University of Oslo, Oslo, Norway.
authors.forename: Hege G
authors.initials: HG
authors.lastname: Russnes
authors.affiliation: Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
authors.forename: Carlos
authors.initials: C
authors.lastname: Caldas
mesh_terms: D000818:Animals; D054736:Elongation Factor 2 Kinase / Q000378:metabolism*; D005260:Female; D017353:Gene Deletion; D006801:Humans; D051059:PTEN Phosphohydrolase / Q000235:genetics*; D064726:Triple Negative Breast Neoplasms / Q000201:enzymology*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D016159:Tumor Suppressor Protein p53; D054736:Elongation Factor 2 Kinase; D051059:PTEN Phosphohydrolase